Frequency Therapeutics, Inc.

NasdaqCM:FREQ Voorraadrapport

Marktkapitalisatie: US$547.3m

Frequency Therapeutics Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

David Lucchino

Algemeen directeur

US$3.2m

Totale compensatie

Percentage CEO-salaris19.9%
Dienstverband CEO9yrs
Eigendom CEO1.7%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur7.2yrs

Recente managementupdates

Recent updates

Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

Jan 01
Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Jan 19
Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year

Aug 18
Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year

Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

Jul 31
Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

Frequency Therapeutics (FREQ) Investor Presentation - Slideshow

Jun 18

Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout

Apr 21

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be

Apr 04
Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be

We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

Mar 15
We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns

Jan 22
If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns

Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?

Dec 27
Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?

Frequency Therapeutics to host investor event in early January next year

Dec 18

How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?

Dec 10
How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 19
Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Frequency Therapeutics EPS beats by $0.16, beats on revenue

Nov 16

Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 Results

Nov 09

Analyse CEO-vergoeding

Hoe is David Lucchino's beloning veranderd ten opzichte van Frequency Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2023n/an/a

-US$59m

Jun 30 2023n/an/a

-US$67m

Mar 31 2023n/an/a

-US$78m

Dec 31 2022US$3mUS$630k

-US$82m

Sep 30 2022n/an/a

-US$86m

Jun 30 2022n/an/a

-US$91m

Mar 31 2022n/an/a

-US$88m

Dec 31 2021US$6mUS$600k

-US$85m

Sep 30 2021n/an/a

-US$73m

Jun 30 2021n/an/a

-US$54m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020US$5mUS$551k

-US$27m

Sep 30 2020n/an/a

-US$22m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$19m

Dec 31 2019US$7mUS$442k

-US$20m

Sep 30 2019n/an/a

-US$20m

Jun 30 2019n/an/a

-US$23m

Mar 31 2019n/an/a

-US$21m

Dec 31 2018US$744kUS$367k

-US$19m

Compensatie versus markt: De totale vergoeding ($USD 3.16M ) David } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.16M ).

Compensatie versus inkomsten: De vergoeding van David is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

David Lucchino (53 yo)

9yrs

Tenure

US$3,159,278

Compensatie

Mr. David L. Lucchino is a Co-Founder of Frequency Therapeutics, Inc. and has been its Chief Executive Officer and President since November 2014. Mr. Lucchino served as Treasurer and Secretary of Frequency...

Bestuursleden

NaamPositieTenureCompensatieEigendom
David Lucchino
Co-Founder9yrsUS$3.16m1.73%
$ 9.5m
John LaMattina
Senior Advisor & Member of PCA Regenerative Medicine Advisory Board6.7yrsgeen gegevensgeen gegevens
Timothy Barberich
Independent Vice Chairman7.2yrsUS$104.32k0.22%
$ 1.2m
Robert Langer
Independent Director & Member of PCA Regenerative Medicine Advisory Board7.2yrsUS$133.32k0.66%
$ 3.6m
Cynthia Feldmann
Independent Director3.2yrsUS$92.82k0%
$ 0
Kenneth Anderson
Member of PCA Regenerative Medicine Advisory Boardno datageen gegevensgeen gegevens
Ralph Mazitschek
Member of PCA Regenerative Medicine Advisory Boardno datageen gegevensgeen gegevens
Jeffrey Karp
Member of PCA Regenerative Medicine Advisory Boardno datageen gegevensgeen gegevens
Stephen Haggarty
Member of PCA Regenerative Medicine Advisory Boardno datageen gegevensgeen gegevens
Xiaolei Yin
Member of PCA Regenerative Medicine Advisory Boardno datageen gegevensgeen gegevens
Daniel Lee
Member of Clinical Advisory Boardno datageen gegevensgeen gegevens
Joni Doherty
Member of Clinical Advisory Boardno datageen gegevensgeen gegevens

7.2yrs

Gemiddelde duur

72.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van FREQ wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.2 jaar).